Attached files

file filename
EX-32.1 - EX-32.1 - LIGAND PHARMACEUTICALS INClgnd_123120xexhibit321.htm
EX-31.2 - EX-31.2 - LIGAND PHARMACEUTICALS INClgnd_123120xexhibit312.htm
EX-31.1 - EX-31.1 - LIGAND PHARMACEUTICALS INClgnd_123120xexhibit311.htm
EX-21.1 - EX-21.1 - LIGAND PHARMACEUTICALS INClgnd_123120xexhibit211.htm
EX-10.72 - EX-10.72 - LIGAND PHARMACEUTICALS INCligandcydexex1072_gileadsu.htm
EX-10.69 - EX-10.69 - LIGAND PHARMACEUTICALS INCligand-ex1069xbondhedgeame.htm
EX-10.68 - EX-10.68 - LIGAND PHARMACEUTICALS INCexhibit1068.htm
EX-10.67 - EX-10.67 - LIGAND PHARMACEUTICALS INCexhibit1067_bondhedgexbarc.htm
EX-10.1 - EX-10.1 - LIGAND PHARMACEUTICALS INCexhibit101_ligand-2002stoc.htm
EX-4.3 - EX-4.3 - LIGAND PHARMACEUTICALS INCexhibit43_ligand-descripti.htm
10-K - 10-K - LIGAND PHARMACEUTICALS INClgnd-20201231.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:
 
(1) Registration Statement (Form S-8 No. 333-252480) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,

(2) Registration Statement (Form S-8 No. 333-233130) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,

(3) Registration Statement (Form S-8 No. 333-212775) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,

(4) Registration Statement (Form S-8 No. 333-182547) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,

(5) Registration Statement (Form S-8 No. 333-160132) pertaining to the 2002 Stock Incentive Plan, as amended and restated, and Employee Stock Purchase Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, and

(6) Registration Statement (Form S-8 No. 333-131029) pertaining to the 2002 Stock Incentive Plan and 2002 Employee Stock Purchase Plan of Ligand Pharmaceuticals Incorporated;
  
of our reports dated February 24, 2021, with respect to the consolidated financial statements of Ligand Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Ligand Pharmaceuticals Incorporated included in this Annual Report (Form 10-K) of Ligand Pharmaceuticals Incorporated for the year ended December 31, 2020.
 

/s/ Ernst & Young LLP
 
San Diego, California
February 24, 2021